- Home
- PLX vs KF Comparison
PLX vs KF Comparison
Compare PLX & KF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLX | KF |
|---|---|---|
| Founded | 1993 | 1984 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.0M | 197.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLX | KF |
|---|---|---|
| Price | $2.97 | $48.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 18.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.29 | N/A |
| Revenue Next Year | $16.65 | N/A |
| P/E Ratio | $43.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $18.30 |
| 52 Week High | $3.10 | $25.56 |
Technical Indicators
Market Signals| Indicator | PLX | KF |
|---|---|---|
| Relative Strength Index (RSI) | 72.63 | 72.03 |
| Support Level | $2.81 | $45.21 |
| Resistance Level | $3.03 | $50.00 |
| Average True Range (ATR) | 0.17 | 1.46 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 93.00 | 81.92 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.